27
Mar

Denmark’s Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.

…read more

Source: Genmab banks $22M from J&J as myeloma drug ticks forward

    

0 No comments